Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report [PDF]
Journal of Liver Cancer, 2022 There are various methods for treating advanced hepatocellular carcinoma with portal vein invasion, such as systemic chemotherapy, transarterial chemoembolization, transarterial radioembolization, and concurrent chemoradiotherapy.
In-Jung Kim +5 more
doaj +1 more source
Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. [PDF]
, 2016 Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options.
Alanis, Lourdes +3 more
core +1 more source
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]
, 2015 Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W +2 more
core +2 more sources
Locoregional Transarterial Therapies for Hepatocellular Carcinoma: Transarterial Chemoembolization and Radioembolization [PDF]
Visceral Medicine, 2013 <b><i>Background: </i></b>Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related mortality. Despite the widespread implementation of surveillance programs, more than half of the patients with HCC are diagnosed at late stages, when curative treatments ...
Mercedes Iñarrairaegui +2 more
openaire +1 more source
Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity [PDF]
, 2017 Aim: Compare radioembolization (Y90) and chemoembolization (CE) for the treatment of unresectable intrahepatic cholangiocarcinoma (UICC). Materials & methods: Institutional Review Board-approved, retrospective search was performed.
Akinwande, Olaguoke +6 more
core +2 more sources
Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres
BioMed Research International, 2018 Liver malignancies, either primary tumours (mainly hepatocellular carcinoma and cholangiocarcinoma) or secondary hepatic metastases, are a major cause of death, with an increasing incidence. Among them, hepatocellular carcinoma (HCC) presents with a dark prognosis because of underlying liver diseases and an often late diagnosis.
Bouvry, C. +6 more
openaire +5 more sources
Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma
Zhongliu Fangzhi Yanjiu, 2022 Primary hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world, and ranks third in tumor-related deaths. The incidence and mortality of HCC in China are among the top five in both men and women, and are increasing year by ...
ZHOU Shi
doaj +1 more source
Treatment options for PNET liver metastases. a systematic review [PDF]
, 2018 Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo +8 more
core +1 more source
First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI) [PDF]
, 2012 The objective of this pilot clinical study was to assess the safety, technical feasibility, pharmacokinetic (PK) profile and tumour response of DC Bead™ with irinotecan (DEBIRI™) delivered by intra-arterial embolisation for the treatment of metastatic ...
Eichler, Katrin +6 more
core +1 more source
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis [PDF]
Clinical and Molecular Hepatology, 2015 Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited.
Hyun Young Woo, Jeong Heo
doaj +1 more source